Sunshine Biopharma Inc. — fact timeline

Sunshine Biopharma Inc. shareholders approved to the voluntary adjustment, from time to time, of the exercise price of any and all currently outstanding Series C Warrants pursuant to Section 3.8 of the Series C Warrants. at the 2026-05-28 meeting.

“to the voluntary adjustment, from time to time, of the exercise price of any and all currently outstanding Series C Warrants pursuant to Section 3.8 of the Series C Warrants.”

Sunshine Biopharma Inc. shareholders approved to any adjustment to the exercise price or number of shares of common stock underlying the Series C Warrants issued in the Offering in the event of a Share Combination Event pursuant to Section 3.7 of the Series C Warrants. at the 2026-05-28 meeting.

“to any adjustment to the exercise price or number of shares of common stock underlying the Series C Warrants issued in the Offering in the event of a Share Combination Event pursuant to Section 3.7 of the Series C Warrants.”

Sunshine Biopharma Inc. shareholders approved to issue in excess of twenty percent (20%) of the outstanding shares of the Company’s common stock at a deemed discount to the Nasdaq Minimum Price (as defined in Nasdaq Listing Rule 5635(d)(1)(A)) immediately prior to execution of the Placement Agent Agreement for the Company’s public offering that at the 2026-05-28 meeting.

“to issue in excess of twenty percent (20%) of the outstanding shares of the Company’s common stock at a deemed discount to the Nasdaq Minimum Price (as defined in Nasdaq Listing Rule 5635(d)(1)(A)) immediately prior to execution of the Placement Agent Agreement for the Company’s public offering that closed on May 19, 2026 (the “Offering”).”

Sunshine Biopharma Inc. entered into Placement Agent Agreement with Aegis Capital Corp. valued at approximately $6 million (effective 2026-05-18).

“On May 18, 2026, Sunshine Biopharma Inc. (the “Company”) entered into a placement agent agreement (the “Placement Agent Agreement”) with Aegis Capital Corp. (the “Placement Agent”), in connection with a best efforts public offering”

Sunshine Biopharma Inc. reported the year ended December 31, 2025 results: revenue $36.3 million.

“specific reference in such filing. --- EX-99.1 (PRESS RELEASE) --- EX-99.1 2 sunshine_ex9901.htm PRESS RELEASE Exhibit 99.1 Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year FORT LAUDERDALE, FL / ACCESSWIRE / April 6, 2026 — Sunshine Biopharma Inc. (NASDAQ: SBFM) (“Sunshine Biopharma” or the “Company”), a”

Sunshine Biopharma Inc. engaged M&K CPAS, PLLC as its auditor.

“ublic accounting firm and retained M&K CPAS, PLLC (“M&K”) as its independent auditor. The decision to dismiss Bush & Associates and retain M&K was approved by the unanimous consent of the Company’s board of directors and the Company’s”

Sunshine Biopharma Inc. dismissed Bush & Associates CPA LLC as its auditor.

“Effective September 24, 2025, Sunshine Biopharma Inc. (the “Company”), dismissed Bush & Associates CPA LLC (“Bush & Associates”), as its independent registered public accounting firm and retained M&K CPAS, PLLC (“M&K”) as its independent auditor.”

Michel Roy was appointed as Chief Commercial Officer at Sunshine Biopharma Inc..

“On January 13, 2025, Sunshine Biopharma Inc. (the “Company”) appointed Mr. Michel Roy as the Company’s Chief Commercial Officer.”

Sunshine Biopharma Inc. engaged Bush & Associates CPA LLC as its auditor.

“Sunshine Biopharma, Inc. (the “Company”), retained Bush & Associates CPA LLC (“Bush & Associates”), as its independent registered public accounting firm.”

Sunshine Biopharma Inc. dismissed BF Borgers CPA, PC as its auditor.

“udited by BF Borgers CPA, PC (“Borgers”). On May 3, 2024, the Securities and Exchange Commission (the “SEC”)”

Sunshine Biopharma Inc.: Filed certificate of amendment to articles of incorporation to effect a 1-for-100 reverse stock split (effective 2024-04-17).

“Effective April 17, 2024, Sunshine Biopharma, Inc. (the “Company”) filed a certificate of amendment to its articles of incorporation with the Secretary of State of Colorado to effect a 1-for-100 reverse split of the Company’s common stock.”

Sunshine Biopharma Inc. reported the fiscal year ended December 31, 2023 results: revenue $ 24,092,787, net income $ 4,506,044, EPS negative $0.19 per share.

“The following are key items contained in the Company’s Income Statement included in the 2023 10-K: 2023 2022 Sales $ 24,092,787 $ 4,345,603 Gross Profit $ 8,339,171 $ 1,696,575 General & Administrative Expenses $ 13,124,470 $ 28,697,325 Goodwill impairment $ – $ 18,326,719 Net Loss $ 4,506,044 $ 26,744,440”

Sunshine Biopharma Inc. shareholders approved Reverse stock split of the Company’s common stock at a ratio up to 1-for-200 at the 2024-03-04 meeting.

“On March 4, 2024, Dr. Slilaty, as the holder of the majority of the voting power of the stockholders of the Company, approved by written consent to effect a reverse stock split of the Company’s common stock at a ratio up to 1-for-200.”

Sunshine Biopharma Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii)).

“February 28, 2024, the Company received a notification letter from Nasdaq advising that Nasdaq’s staff had determined that as of February 27, 2024, the Company’s common stock had a closing bid price of $0.10 or less for ten consecutive trading days and accordingly, the Company was subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). Accordingly, Nasdaq determined to remove the Company’s securities from listing and registration on The Nasdaq Stock Market, subject to the procedures set forth in the Nasdaq Listing Rule 5800 Series which prov”

Sunshine Biopharma Inc. shareholders approved Give full effect to the adjustment in the exercise price and number of Warrant Shares as defined in the Series B Warrants following a Dilutive Issuance as defined in the Series B Warrants pursuant to Section 3.2 of the Series B Warrants at the 2024-02-13 meeting.

“On February 13, 2024, Dr. Steve Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma, Inc. (the “Company”), approved by written consent: · to give full effect to alternative cashless exercises pursuant to Section ‎2.3 of the Series A Warrants (the “Series A Warrants”) issued pursuant to the underwriting agreement (the “Underwriting Agreement”), dated February 13, 2024, between the Company and Aegis Capital Corp., as underwriter; · to any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants (issued pursuant to the Underwriting Agreement) (the “Series B Warrants,” and collectively with the Series A Warrants, the “Warrants”) in the event of a Share Combination Event (as defined in the Series A Warrants and Series B Warrants) in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warrants; · to the voluntary adjustment, from time to time, of the exercise price”

Sunshine Biopharma Inc. shareholders approved Render inapplicable clause (i) of the definition of the Floor Price as defined in the Series B Warrant in Section 3.2 of the Series B Warrants at the 2024-02-13 meeting.

“On February 13, 2024, Dr. Steve Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma, Inc. (the “Company”), approved by written consent: · to give full effect to alternative cashless exercises pursuant to Section ‎2.3 of the Series A Warrants (the “Series A Warrants”) issued pursuant to the underwriting agreement (the “Underwriting Agreement”), dated February 13, 2024, between the Company and Aegis Capital Corp., as underwriter; · to any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants (issued pursuant to the Underwriting Agreement) (the “Series B Warrants,” and collectively with the Series A Warrants, the “Warrants”) in the event of a Share Combination Event (as defined in the Series A Warrants and Series B Warrants) in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warrants; · to the voluntary adjustment, from time to time, of the exercise price”

Sunshine Biopharma Inc. shareholders approved Voluntary adjustment, from time to time, of the exercise price of any and all currently outstanding Warrants pursuant to Section 3.8 of the Series A Warrants and 3.9 of the Series B Warrants at the 2024-02-13 meeting.

“On February 13, 2024, Dr. Steve Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma, Inc. (the “Company”), approved by written consent: · to give full effect to alternative cashless exercises pursuant to Section ‎2.3 of the Series A Warrants (the “Series A Warrants”) issued pursuant to the underwriting agreement (the “Underwriting Agreement”), dated February 13, 2024, between the Company and Aegis Capital Corp., as underwriter; · to any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants (issued pursuant to the Underwriting Agreement) (the “Series B Warrants,” and collectively with the Series A Warrants, the “Warrants”) in the event of a Share Combination Event (as defined in the Series A Warrants and Series B Warrants) in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warrants; · to the voluntary adjustment, from time to time, of the exercise price”

Sunshine Biopharma Inc. shareholders approved Any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants in the event of a Share Combination Event as defined in the Series A Warrants and Series B Warrants in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warra at the 2024-02-13 meeting.

“On February 13, 2024, Dr. Steve Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma, Inc. (the “Company”), approved by written consent: · to give full effect to alternative cashless exercises pursuant to Section ‎2.3 of the Series A Warrants (the “Series A Warrants”) issued pursuant to the underwriting agreement (the “Underwriting Agreement”), dated February 13, 2024, between the Company and Aegis Capital Corp., as underwriter; · to any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants (issued pursuant to the Underwriting Agreement) (the “Series B Warrants,” and collectively with the Series A Warrants, the “Warrants”) in the event of a Share Combination Event (as defined in the Series A Warrants and Series B Warrants) in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warrants; · to the voluntary adjustment, from time to time, of the exercise price”

Sunshine Biopharma Inc. shareholders approved Give full effect to alternative cashless exercises pursuant to Section 2.3 of the Series A Warrants at the 2024-02-13 meeting.

“On February 13, 2024, Dr. Steve Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma, Inc. (the “Company”), approved by written consent: · to give full effect to alternative cashless exercises pursuant to Section ‎2.3 of the Series A Warrants (the “Series A Warrants”) issued pursuant to the underwriting agreement (the “Underwriting Agreement”), dated February 13, 2024, between the Company and Aegis Capital Corp., as underwriter; · to any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants (issued pursuant to the Underwriting Agreement) (the “Series B Warrants,” and collectively with the Series A Warrants, the “Warrants”) in the event of a Share Combination Event (as defined in the Series A Warrants and Series B Warrants) in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warrants; · to the voluntary adjustment, from time to time, of the exercise price”

Sunshine Biopharma Inc. entered into Underwriting Agreement with Aegis Capital Corp. valued at approximately $10.0 million (effective 2024-02-13).

“On February 13, 2024, Sunshine Biopharma, Inc., (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Aegis Capital Corp. (the “Underwriter”), in connection with a firm commitment underwritten public offering (the “Offering”)”

Dr. Abderrazzak Merzouki was elected as Chief Science Officer at Sunshine Biopharma Inc..

“Previously, Dr. Merzouki had held the position of Chief Operating Officer.”

Malek Chamoun was appointed as Chief Development Officer at Sunshine Biopharma Inc..

“Malek Chamoun, age 39 , was appointed as our Chief Development Officer in January 2024.”

Marc Beaudoin was appointed as Chief Operating Officer at Sunshine Biopharma Inc..

“Marc Beaudoin, age 57, was appointed as our Chief Operating Officer in January 2024.”

Sunshine Biopharma Inc. shareholders approved Advisory vote on frequency of future advisory votes on executive compensation at the 2023-12-07 meeting.

“Advisory vote on frequency of future advisory votes on executive compensation. 1 YEAR 2 YEARS 3 YEARS ABSTAIN BROKER NON-VOTE 1,777,275 165,011 15,063,931 923,289 5,040,953”

Sunshine Biopharma Inc. shareholders approved Advisory vote on executive compensation at the 2023-12-07 meeting.

“Advisory vote on executive compensation. FOR AGAINST ABSTAIN BROKER NON-VOTE 16,196,664 1,516,235 216,607 5,040,953”

Sunshine Biopharma Inc. shareholders approved Approval of a reverse stock split of the Company’s common stock by a ratio of not less than 1-for-2 and not more than 1-for-40 at the 2023-12-07 meeting.

“Approval of reverse stock split. FOR AGAINST ABSTAIN 20,005,507 2,657,164 307,788”

Sunshine Biopharma Inc. shareholders approved Approval of the Company’s 2023 Equity Incentive Plan at the 2023-12-07 meeting.

“Approval of the Company’s 2023 Equity Incentive Plan. FOR AGAINST ABSTAIN BROKER NON-VOTE 15,915,610 1,842,630 171,266 5,040,953”

Sunshine Biopharma Inc. shareholders approved Ratification of the board of directors’ appointment of BF Borgers, CPA P.C. as the Company’s independent registered public accounting firm for 2023 at the 2023-12-07 meeting.

“Ratification of the board of directors’ appointment of BF Borgers, CPA P.C. as the Company’s independent registered public accounting firm for 2023. FOR AGAINST ABSTAIN 20,099,526 2,452,753 418,180”

Sunshine Biopharma Inc. shareholders approved Election of directors at the 2023-12-07 meeting.

“At the meeting, (i) Dr. Steve N. Slilaty, Dr. Abderrazzak Merzouki, Dr. Rabi Kiderchah, Mr. David Natan, and Dr. Andrew Keller were each elected as directors of the Company to serve until the next annual meeting of stockholders or until their successors have been elected and qualified”

Sunshine Biopharma Inc. reported the quarter ended September 30, 2023 results: revenue $5,957,668, net income net loss of $651,482 ($0.04 per share).

“Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its quarterly report for the 2023 third quarter. The Company reported gross revenues of $5,957,668 for the quarter ended September 30, 2023, an increase of $5,824,860 over the same period in 2022.”

Sunshine Biopharma Inc. terminated Research Agreement with Jewish General Hospital (JGH) valued at termination of Research Agreement for Adva-27a IND-enabling studies (effective 2023-12-02).

“On November 2, 2023, the Company provided notice to JGH of its termination of the Research Agreement, which will become effective on December 2, 2023, pursuant to the terms of the Research Agreement.”

Sunshine Biopharma Inc. amended Warrant Agent Agreement with Equiniti Trust Company valued at Amendment to Warrant Agent Agreement reducing exercise price to $0.11 and eliminating prohibition on (effective 2023-10-18).

“On October 18, 2023, Sunshine Biopharma, Inc. (the “Company”) entered into an amendment to the Warrant Agent Agreement, dated February 17, 2022 (the “Warrant Agent Agreement”), between the Company and Equiniti Trust Company to (i) reduce the exercise price of the outstanding warrants issued by the Company on February 17, 2022 to $0.11, subject to further adjustment as provided therein, and (ii) eliminate the provision under the Warrant Agent Agreement that prohibits the Company’s chief executive officer, Dr. Steve N. Slilaty, from exercising his voting rights under his Series B Preferred Stock of the Company.”

Sunshine Biopharma Inc. shareholders approved Amend the Warrant Agent Agreement to reduce the exercise price of Tradeable Warrants to $0.11 and eliminate the provision prohibiting the CEO from exercising voting rights under his Series B Preferred Stock at the 2023-10-12 meeting.

“Holders of 736,242 Tradeable Warrants voted in favor of the amendment (representing 76.4% of 963,693 outstanding Tradeable Warrants), votes against were 62,429, and there were 3,930 abstentions.”

Sunshine Biopharma Inc. reported the 2023 second quarter results: revenue $5,560,865.

“of therapeutic areas including oncology and antivirals today announced that it has filed its quarterly report for the 2023 second quarter. The Company reported gross revenues of $5,560,865 for the quarter ended June 30, 2023, an increase of 3,600% over the same period in 2022. The increase was largely due to the prescription drugs sales of Nora Pharma Inc., a”

Sunshine Biopharma Inc. entered into Placement Agent Agreement with Aegis Capital Corp. valued at Commission of 10% of gross proceeds, 2% expense allowance, and 10% of proceeds from warrant exercise (effective 2023-05-12).

“Aegis Capital Corp. (“Aegis”) acted as the placement agent in connection with the Private Placement. Pursuant to the placement agent agreement between the Company and Aegis (the “Placement Agent Agreement”), Aegis was paid a commission equal to 10% of the gross proceeds received by the Company in the Private Placement, and a non-accountable expense allowance equal to 2% of the gross proceeds, and will receive 10% of the proceeds from any exercise of Investor Warrants, payable on exercise.”

Sunshine Biopharma Inc. entered into Registration Rights Agreement with accredited and institutional investor valued at Agreement to file a resale registration statement within 15 days of closing, with potential liquidat (effective 2023-05-12).

“In connection with the Purchase Agreement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the investor.”

Sunshine Biopharma Inc. entered into Securities Purchase Agreement with accredited and institutional investor valued at Private placement of common stock, pre-funded warrants, and investor warrants for gross proceeds of (effective 2023-05-12).

“On May 12, 2023, Sunshine Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a certain accredited and institutional investor for a private placement (“Private Placement”) for the Company’s common stock, pre-funded warrants, each exercisable to purchase one share of common stock (“Pre-Funded Warrants”), and warrants, each exercisable to purchase one share of common stock (“Investor Warrants”).”

Sunshine Biopharma Inc.: Amendment to bylaws changing the quorum requirement for common voting stock to one-third of outstanding shares (effective 2023-04-17).

“On April 17, 2023, Sunshine Biopharma, Inc. (the “Company”) adopted an amendment to the Company’s bylaws. Pursuant to the amendment, one-third of the outstanding shares of the Company's common voting stock will constitute a quorum.”

Sunshine Biopharma Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“March 24, 2023, Sunshine Biopharma, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The notification has no immed”

Sunshine Biopharma Inc. entered into Exclusive Patent License Agreement with Arizona Board of Regents on behalf of the University of Arizona (effective 2023-02-24).

“On February 24, 2023, Sunshine Biopharma, Inc. (the “Company”) entered into an Exclusive Patent License Agreement (the “License Agreement”) with Arizona Board of Regents on behalf of the University of Arizona (the “University”).”

Sunshine Biopharma Inc. entered into Research Agreement with Sir Mortimer B. Davis Jewish General Hospital valued at 3% royalty (effective 2023-02-07).

“On February 7, 2023, Sunshine Biopharma, Inc. (the “Company”) received a duly executed research agreement (the “Research Agreement”) with Sir Mortimer B. Davis Jewish General Hospital, a McGill University Health Center hospital located in Montreal, Quebec, Canada (“JGH”) in connection with the Company’s Adva-27a anticancer compound.”

Sunshine Biopharma Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 6, 2022, Sunshine Biopharma, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The notification has no imm”

Rabi Kiderchah was appointed as Director at Sunshine Biopharma Inc..

“The Board added Messrs. Andrew Telsey, JD Kish and Dr. Rabi Kiderchah to serve as directors”

JD Kish was appointed as Director at Sunshine Biopharma Inc..

“The Board added Messrs. Andrew Telsey, JD Kish and Dr. Rabi Kiderchah to serve as directors”

Andrew Telsey was appointed as Director at Sunshine Biopharma Inc..

“The Board added Messrs. Andrew Telsey, JD Kish and Dr. Rabi Kiderchah to serve as directors”